3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Rectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Irinotecan
15
Gemcitabine
14
Paclitaxel
13
Cisplatin
13
alvocidib
11
Oxaliplatin
9
Fluorouracil
9
Taxes
7
Leucovorin
7
Carboplatin
7
Bortezomib
7
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
7
tanespimycin
5
Vorinostat
5
Early Intervention, Educational
5
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
4
Topotecan
3
Sorafenib
3
Doxorubicin
3
Docetaxel
3
Capecitabine
3
Bevacizumab
3
7-hydroxystaurosporine
3
temsirolimus
2
sargramostim
2
ixabepilone
2
eribulin
2
aldesleukin
2
VNP 20009
2
Trastuzumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Unspecified Adult Solid Tumor, Protocol Specific
×
Resveratrol
×
Clear all
NCT00098969
2012-12-17
IRB 2004-535
National Cancer Institute (NCI)
Phase 1
Completed
40 enrolled